Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 9/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | ODC1 | P11926 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258552 | 0.77 | DHODH (0.36) | DHODHIDO1CNR2ELANEPRTN3 | |
| SCHEMBL4250604 | 0.74 | BCHE (0.45) | IDO1BCHEACHEPTPN1ODC1 | |
| SCHEMBL4254312 | 0.73 | MALT1 (0.34) | DHODHIDO1CNR2ELANEPRTN3 | |
| SCHEMBL30062684 | 0.67 | ODC1 (0.47) | IDO1CNR2ODC1PDE4D | |
| SCHEMBL4253859 | 0.65 | BCHE (0.40) | IDO1BCHEACHEPTPN1ODC1 | |
| SCHEMBL21254126 | 0.64 | ACHE (0.41) | IDO1ACHEPTPN1ODC1PDE4D | |
| SCHEMBL4252484 | 0.63 | BCHE (0.46) | IDO1BCHEACHEPTPN1ODC1 | |
| SCHEMBL13779559 | 0.63 | BCHE (0.46) | IDO1BCHEACHEPTPN1ODC1 | |
| SCHEMBL6709228 | 0.63 | IDO1 (0.40) | IDO1BCHEACHEPTPN1ODC1 | |
| Benzoquinone SCHEMBL6765864 | 0.63 | HIF1A (0.39) | IDO1BCHEACHEPTPN1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170926-A1 | Antiviral agents | MONASH UNIVERISTY (AU) | 2009-07-02 | — | — | US | claimed |
| US-20090170926-A1 | Antiviral agents | MONASH UNIVERISTY (AU) | 2009-07-02 | — | — | US | disclosed |
| US-20090170926-A1 | Antiviral agents | MONASH UNIVERISTY (AU) | 2009-07-02 | — | — | US | disclosed |
| US-20090170926-A1 | Antiviral agents | MONASH UNIVERISTY (AU) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170926-A1 | Antiviral agents | SLC10A1, HAVCR2, ZC3HAV1 | DHODH 757/4885IDO1 321/4885BCHE 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.